Hemoglobin A 1c (HbA 1c ) can be used to assess type 2 diabetes (T2D) risk. We asked whether HbA 1c was associated with T2D risk in four scenarios of clinical information availability: 1) HbA 1c alone, 2) fasting laboratory tests, 3) clinic data, and 4) fasting laboratory tests and clinic data.
Since the adoption of hemoglobin A 1c (HbA 1c ) as a biochemical diagnostic criterion for type 2 diabetes (T2D) by the International Expert Committee (IEC) in 2009 (1) , by the American Diabetes Association (ADA) in 2010 (2) , and by the World Health Organization in 2011 (3), HbA 1c is now used worldwide to screen for and diagnose T2D. Individuals with elevated HbA 1c levels in the nondiabetes range have been shown to be at elevated risk for developing T2D (4) (5) (6) (7) . Yet, international groups are not unanimous in their recommendations for the use of HbA 1c to screen for individuals with elevated T2D risk (8, 9) . For instance, the ADA and International Expert Committee recommend HbA 1c of 5.7-6.4% (39-46 mmol/mol) and 6.0-6.4% (42-46 mmol/mol), respectively, to identify prediabetes or an intermediate risk group, whereas the World Health Organization does not include HbA 1c among the recommended tests to identify individuals with elevated T2D risk (10) .
Although fasting glucose (FG) has been the traditional method for assessing T2D risk, HbA 1c has several advantages: it reflects average glucose exposure over time, can be determined in nonfasting patients, has low intraindividual variability and low analytic variability (11) (12) (13) (14) , and has been standardized across laboratories worldwide (15) . Despite these advantages, the utility of measuring HbA 1c for assessing T2D risk in various clinical and nonclinical settings has not been thoroughly evaluated. While it has been shown that the combination of both elevated FG and HbA 1c improved T2D prediction over FG alone (16) , it remains uncertain whether measuring HbA 1c , as part of a comprehensive clinical assessment that includes laboratory testing of fasting individuals, provides additional information for T2D prediction. Alternatively, HbA 1c may be measured in settings where clinical information is limited, e.g., point-of-care testing at a medical center, pharmacy, or core or satellite chemistry laboratory. In these settings, HbA 1c is measured in either nonfasting or fasting blood, sometimes as part of a panel of laboratory tests, but usually without a thorough clinical evaluation of nonblood risk factors.
To address this knowledge gap, we tested the hypothesis that HbA 1c is associated with incident T2D independently of other risk factors assessed in several "real-world" scenarios. In the "HbA 1c -only" scenario, we evaluated the prediction of T2D based only on HbA 1c , age, and sex (i.e., assuming no other information was available, as might be obtained at point-of-care testing). In the "HbA 1c plus fasting laboratory tests" scenario, we assessed the value of measuring HbA 1c in addition to laboratory testing on fasting individuals, including FG, as might be the case in a comprehensive blood analysis. In the "HbA 1c plus clinic visit" scenario, we evaluated the value of adding HbA 1c , as the only laboratory test, to information available at a clinic visit. In the "HbA 1c plus fasting laboratory tests plus clinic visit" scenario, we assessed the value of adding HbA 1c to a clinic-based evaluation that included fasting laboratory testing (17) . We evaluated these scenarios in middle-aged individuals without T2D who were followed for two decades for the development of T2D in two communitybased cohorts: the Framingham Heart Study (FHS) (including white individuals) and the Atherosclerosis Risk in Communities study (ARIC) (including black and white individuals).
RESEARCH DESIGN AND METHODS

FHS and ARIC Study Populations
In FHS, the baseline examination (5th examination) was attended by 3,799 participants in the years 1992-1995. We excluded participants without measured baseline HbA 1c (N = 1,067), any of the other covariates (N = 20), or follow-up data (N = 179). We then excluded individuals who reported use of antidiabetes medications or who had FG $126 mg/dL or HbA 1c $6.5% (48 mmol/mol) (N = 290). Our final study sample was 2,243 white participants. Excluded individuals had characteristics similar to those of included participants (Supplementary  Table 1 ).
In ARIC, the baseline examination (2nd examination) was attended by 14,348 participants in the years 1990-1992. We excluded participants without measured missing baseline HbA 1c (N = 278) or any of the other covariates (n = 515). We then excluded individuals who, in baseline examinations, self-reported a physician diagnosis of T2D or use of antidiabetes medications or who had FG $126 mg/dL or HbA 1c $6.5% (48 mmol/mol) (N = 2,170). As only 91 participants selfidentified as other than white or black, we were unable to examine other racial/ethnic groups in the U.S. Our final study sample was 9,001 white and 2,293 black participants.
The institutional review boards at each study site approved the study protocol, and written informed consent was obtained from all participants.
T2D Incidence
In FHS, incident T2D was defined as FG $126 mg/dL or start of antidiabetes therapy at any of four follow-up examinations over 19 years of follow-up (years 2011-2015). As physician-diagnosed T2D was not a standard question at these examination, we did not include it in the case definition. Follow-up time from the baseline examination (5th examination) was 4 years for the 6th examination, 7 years for the 7th examination, 13.5 years for the 8th examination, and 19 years for the 9th examination.
In ARIC, incident T2D was defined as FG $126 mg/dL, start of antidiabetes therapy, or self-reported physician diagnosis of T2D over a 22-year follow-up period (years 2012-2014). Follow-up time from the baseline examination (2nd examination) was 3 years for the 3rd examination, 6 years for the 4th examination, and 22 years for the 5th examination. Given the long interval between the fourth and fifth examinations, we also identified incident T2D cases by selfreported physician diagnosis of T2D or use of antidiabetes medications from annual telephone interviews for all participants.
Baseline Covariates
Physical examinations included measuring BMI and blood pressure in the sitting position. Self-reported information included race (white or black) and parental history of T2D. HbA 1c was measured in FHS using high-performance liquid chromatography after an overnight dialysis against normal saline to remove the labile fraction (18) . HbA 1c was measured in ARIC using high-performance liquid chromatography, the Tosoh A1c 2. (4, 19) . All instruments were standardized to the Diabetes Control and Complications Trial assay (20) . FG was measured using the hexokinase method in FHS and ARIC. HDL and triglycerides (TG) were determined using a commercially available assay (Hemagen Diagnostics, Inc, Waltham, MA) in FHS (21, 22) and the Roche Cobas Bio analyzer (Roche Diagnostics, Basel, Switzerland) in ARIC (23) .
Statistical Analyses
We performed the analyses in FHS, ARIC whites, and ARIC blacks separately. To display cumulative incidence of T2D by race, we generated Kaplan-Meier curves over the follow-up period, with time to event calculated from the baseline examination to the first diagnosis of incident T2D, death, loss to follow-up, or the last examination.
We constructed four primary prediction models to test the association of HbA 1c with incident T2D adjusted for covariates that represented the clinical information that would be available in four scenarios: 1) The "HbA 1c -only" model was adjusted for age and sex.
2) The "HbA 1c plus fasting laboratory tests" model was adjusted for age, sex, FG, HDL, and TG.
3) The "HbA 1c plus clinic visit" model was adjusted for age, sex, BMI, systolic blood pressure (SBP), and family history of T2D. And 4) the "HbA 1c plus fasting laboratory tests plus clinic visit" model was adjusted for age, sex, BMI, SBP, family history of T2D, FG, HDL, and TG (17) . To fit these models, we used logistic regression in ARIC and generalized estimating equations that accounted for correlation within families in FHS. As HbA 1c in the nondiabetes range has a linear relationship with the log-odds of developing T2D (4), we modeled HbA 1c as a continuous variable.
To estimate the improvement in risk discrimination attributable to HbA 1c , we calculated differences in C statistics between the primary models and their respective nested models that included only the adjustment covariates but not HbA 1c . The C statistic is the probability that a model yields a higher predicted risk for a participant who did develop T2D than another who did not (24) . The change in the C statistic when additional predictors are added to a model reflects their ability to improve risk prediction.
We used SAS (version 9.2 or 9.3; SAS Institute, Cary, NC) or Stata (version 13; StataCorp, College Station, TX) for all analyses. We considered a two-sided P value ,0.05 to be statistically significant for the analysis that tested the primary hypothesis that HbA 1c predicts incident T2D in the "HbA 1c plus fasting laboratory tests plus clinic visit" model.
We performed three sensitivity analyses. First, we repeated the primary analysis using HbA 1c modeled as a binary variable (HbA 1c 5.7-6.4% [39-46 mmol/mol] vs. HbA 1c ,5.7% [39 mmol/mol]). Second, we repeated the analysis for the "HbA 1c -only" and "HbA 1c plus clinic visit" models using an alternative definition of T2D that included only self-reported physician diagnosis and antidiabetes medication use but not FG $126 mg/dL. Third, we repeated the analysis using another alternative definition that included self-reported physician diagnosis, antidiabetes medication use, FG $126 mg/dL, and HbA 1c $6.5% (48 mmol/mol).
Meta-analysis
As we noted heterogeneity between groups based on a Cochran Q statistic (25) (P , 0.05), we combined effect estimates from our primary models across all three groups using DerSimonian and Laird randomeffects meta-analyses that accounted for both within-group and betweengroup variability (26)
Secondary Analyses
First, we conducted secondary analyses to investigate whether HbA 1c was associated with developing T2D in both the short-and long-term. To estimate the short-and long-term risk of T2D, we performed multinomial logistic regression to test the association of HbA 1c with incident T2D modeled as a three-level outcome variable, i.e., no T2D over the follow-up period, incident T2D within the first 8 years, and incident T2D only after 8 years and up to two decades. To account for familial correlation in FHS, we performed mixed-effects multinomial logistic regression. Second, to determine whether HbA 1c was associated with incident T2D in both those with and those without impaired FG (IFG), we performed stratified analyses by FG $100 mg/dL vs. FG ,100 mg/dL.
Absolute Risk Estimation
The concept of absolute T2D risk associated with a specific HbA 1c value may be more clinically useful and easily conceptualized by some patients compared with relative risk. Absolute risks can be reported to patients to define personal risk and be compared with population-normative standards to identify actionable thresholds. To do this, we pooled data from FHS and ARIC and generated predicted probabilities of incident T2D (i.e., absolute risks) from a logistic regression model that adjusted HbA 1c for race, cohort, age, and sex. We also generated the predicted probabilities of developing T2D over the short-term and long-term using multinomial logistic regression on the three-level outcome variable.
We displayed the predicted probabilities using box plots by 11 HbA 1c levels of 0.2%-point increments from 4.5-6.5% (26-48 mmol/mol) to identify HbA 1c levels with predicted risk probabilities that were higher than the average risk of incident T2D in middle-aged adults in the U.S., defined by the annual incidence of diagnosed T2D for U.S. adults aged 45-64 years in 2014, estimated by the Centers for Disease and Control Prevention at 10.5 per 1,000 persons (27). Thus, we defined high risk as a predicted probability of T2D $0.21 (20 * 10.5/1,000 = 0.21) over 20 years or .0.08 (8 * 10.5/1,000 = 0.08) over the first 8 years.
As 
RESULTS
Participants who developed T2D had higher BMI, SBP, TG, FG, and HbA 1c and lower HDL and were more likely to have a T2D family history compared with those who did not develop T2D. ARIC blacks had a slightly higher proportion of women and higher BMI and HbA 1c than ARIC whites (Table 1) . In all four models, each 1%-unit increase in HbA 1c was associated with a 2.7-to 4.5-fold higher incidence of T2D in FHS whites, ARIC whites, and ARIC blacks, as well as in the meta-analysis of these three groups ( Fig. 1 Table 6 ).
While the association between HbA 1c and incident T2D in ARIC differed according to race in the "HbA 1c -only" model (P interaction = 0.01), there was no difference after adjustment for other covariates in the "HbA 1c plus fasting laboratory tests plus clinic visit" model (P interaction = 0.11) (Supplementary Table 7 ). KaplanMeier curves showed clear separation of the curves for HbA 1c $5.7% (39 mmol/mol) vs. ,5.7% (39 mmol/mol) in blacks (ARIC) and whites (pooled across ARIC and FHS) (log-rank P , 0.001) (Fig. 2) . Incidence of T2D was similar between blacks and whites with HbA 1c .5.7% (39 mmol/mol) (log-rank P = 0.25).
In FHS, HbA 1c improved the predictive performance in the "HbA 1c -only" model and "HbA 1c -clinic visit" model (difference in C statistic, P , 0.05). In ARIC, HbA 1c improved the predictive performance in all four models and in both races (difference in C statistic, P , 0.001) ( Table 2) . Addition of clinical predictors from the "HbA 1c plus fasting laboratory tests plus clinic visit" model to a base model with only HbA 1c improved its predictive performance significantly (P , 0.05) (Supplementary Table 8 ).
In all four models, higher HbA 1c was associated with increased T2D risk in both participants with and without IFG. Among FHS whites, ARIC whites, and ARIC blacks with IFG, the meta-analytic odds ratio (OR) for the "HbA 1c plus fasting laboratory tests plus clinic visit" model was 3.14 (95% CI 2.67, 3.69) per 1%-unit increase. Among those without IFG, the meta-analytic OR was 2.20 (95% CI 1.68, 2.88) per 1%-unit increase (Supplementary Table 9 ). HbA 1c improved the predictive performance when added to each of the four models in FHS whites, ARIC whites, and ARIC blacks with IFG (difference in C statistic, P , 0.05) (Supplementary Table 10 ).
In secondary analyses, higher HbA 1c was associated with higher T2D risk both in the short-term (within 8 years of the baseline visit) and in the long-term (T2D incidence .8 years after the baseline visit). The meta-analytic OR for the "HbA 1c plus fasting laboratory tests plus clinic visit" model was 5.79 (95% CI 2.51, 13.36) per 1%-unit increase for short-term T2D and 2.23 (95% CI 1.94, 2.57) for longterm T2D (Supplementary Table 11 ).
Higher HbA 1c was associated with higher absolute risk for incident T2D over the 20-year follow-up period (Fig. 3A) . Likewise, the predicted absolute risk We excluded from this analysis individuals who, in baseline examinations, self-reported a physician diagnosis of T2D or use of antidiabetes medications or had FG $126 mg/dL or HbA 1c $6.5% (48 mmol/mol) at baseline. To convert FG to mmol/L, multiply by 0.0555; to convert cholesterol to mmol/L, multiply by 0.0259; and to convert TG to mmol/L, multiply by 0.0113. Race was self-reported; BMI is calculated as weight in kilograms divided by the square of height in meters. Follow-up time was calculated from the baseline examination to the first diagnosis of incident T2D at either an examination visit or in a telephone survey, death, last appearance at an examination visit, or the last examination visit. *P , 0.05 for t tests and x 2 tests, which test for differences in baseline characteristics between those who developed T2D and those who did not in FHS, ARIC whites, and ARIC blacks. increased in a graded fashion with higher HbA 1c values over both short-term (within 8 years) and long-term (only after 8 years) follow-up (Fig. 3B) . The predicted absolute risk of T2D over the 20-year follow-up period was higher for each successive HbA 1c level (,5.4, 5.4-5.7, 5.7-6.0, and $6.0%) within each FG level (,100, 100-109, and $110 mg/dL) (Fig. 3C) . In  Fig. 3D , the 75th percentile of predicted probabilities was ,0.08 for all HbA 1c -FG categories with HbA 1c ,5.4%, indicating that .75% of participants with HbA 1c ,5.4% had less-than-average 8-year risk regardless of FG level.
HbA 1c levels of $5.4% (36 mmol/mol), $5.7% (39 mmol/mol), and $6.0% (42 mmol/mol) had PPV of 90%, 97%, and 99% and NPV of 78%, 56%, and 46%, respectively, for being at aboveaverage 20-year risk and PPV of 51%, 89%, and 100% and NPV of 100%, 94%, and 80%, respectively, for being at above-average 8-year risk. After we accounted for FG, HbA 1c levels of $5.4% (36 mmol/mol), $5.7% (39 mmol/mol), and $6.0% (42 mmol/mol) had PPV of 72%, 86%, and 93% and NPV of 76%, 63%, and 69%, respectively, for above-average 20-year risk and PPV of 40%, 59%, and 78% and NPV of 94%, 88%, and 81%, respectively, for aboveaverage 8-year risk (Supplementary Table  12 (4) .
In the Coronary Artery Risk Development in Young Adults study, HbA 1c modestly improved the predictive performance of a model composed of clinical and fasting laboratory test variables in both black and white participants followed for 5 years (45) . Here, we showed that HbA 1c was strongly associated with higher T2D risk in both black and white participants from FHS and ARIC who were followed for two decades. Our analysis of short-and long-term risk implied that the elevated risk of developing T2D associated with a higher HbA 1 extends well beyond 8 years even if an individual remains T2D free in the shortterm in each of the scenarios tested.
To assess the ability for HbA 1c to predict T2D at the population level over other clinical predictors, we calculated the difference in C statistic after adding HbA 1c to models composed of covariates representing the available information in each of the four scenarios. We showed that HbA 1c significantly improves the identification of individuals who are more likely than others from the population to develop T2D even when demographic and nonblood predictors have been obtained. The improvement is, however, minimal when fasting laboratory test measures have also been obtained. Nevertheless, in clinical situations where the status of a specific patient's risk factors (including FG) are known, HbA 1c remains a strong independent predictor of T2D, where each 1%-unit increase in HbA 1c is associated with a two-to threefold T2D risk. This higher risk of developing T2D in the next 20 years associated with a 1%-unit increase in HbA 1c can be communicated to patients to motivate strategies for T2D prevention.
T2D screening and prediction in people without overt symptoms of hyperglycemia has potential value for early detection and treatment that, in turn, may In all four models, each 1%-unit increase in HbA 1c was associated with a 2.7-to 4.5-fold higher incidence of T2D in FHS whites, ARIC whites, and ARIC blacks, as well as in the meta-analysis of these three groups. "HbA 1c -only" model: adjusted for age and sex; "HbA 1c + fasting laboratory tests" model: adjusted for age, sex, FG, TG, and HDLs; "HbA 1c + clinic visit" model: adjusted for age, sex, SBP, family history of T2D, and BMI; "HbA 1c + fasting laboratory tests + clinic visit" model: adjusted for age, sex, FG, TG, HDLs, SBP, family history of T2D, and BMI. As we observed heterogeneity in the effect estimates, we performed the metaanalysis using random effects. OR, OR per 1%-unit increase in HbA 1c ; I-squared, Higgins I 2 test for heterogeneity.
reduce T2D-related complications (5, 46, 47) . We have demonstrated that HbA 1c has high predictive performance for incident T2D and is therefore effective for identifying high-risk individuals so that preventive measures can be targeted at those who may need them the most. Our results show that HbA 1c is an independent predictor of T2D in people with strictly normal FG and in people with IFG, suggesting that measuring HbA 1c in addition to FG may further improve risk assessment. While FG and HbA 1c individually have high predictive performance for incident T2D in longitudinal studies (5, (31) (32) (33) (34) (35) (36) (37) (38) , current clinical cut points for HbA 1c or FG alone have low sensitivity for detecting T2D and prediabetes defined by oral glucose tolerance tests in crosssectional examinations (48, 49) . Nevertheless, FG and HbA 1c are highly preferred over oral glucose tolerance tests as screening tests because of their ease of administration, greater acceptability to patients, and lower cost and clear predictive ability for long-term clinical outcomes (10) .
As the association of HbA 1c with T2D risk is observed across the entire spectrum of the nondiabetes range of HbA 1c (4), suitable thresholds to define prediabetes continue to be debated (50) . In this investigation, we evaluated HbA 1c cutoffs $5.7% (39 mmol/mol) and $6.0% (42 mmol/mol) for their ability to identify individuals with elevated 20-year T2D risk and found that these thresholds had high PPV for elevated risk with and without accounting for FG but only mediocre NPV, suggesting that applying these thresholds would effectively "rule in" but not "rule out" high 20-year T2D risk.
An advantage of measuring HbA 1c for risk stratification is in situations where a fasting blood sample for laboratory testing is not available or when overnight fasting is inconvenient, such as for patients who would need to return on a separate day for testing or travel great distances to test centers. Therefore, another effective use of HbA 1c would be to identify low-risk individuals who do not require fasting laboratory testing. While none of the three thresholds tested had high NPV to "rule out" individuals with high 20-year T2D risk, HbA 1c ,5.4% (36 mmol/mol) had a high NPV to effectively "rule out" high 8-year T2D risk even after accounting for FG, implying that additional fasting laboratory testing to improve stratification of short-term T2D risk for these patients may be redundant and only incur unnecessary expense and inconvenience. Point-of-care HbA 1c testing during health maintenance visits may be adequate for these patients until their HbA 1c increases to 5.4% (36 mmol/mol) or above.
This study has several strengths. Our scenarios were constructed to be generic and therefore generalizable to different health systems that use HbA 1c for T2D prediction. As the risk estimates and prediction equations were obtained from large HbA 1c to be an even better predictor of T2D than reported herein. Owing to small sample sizes, races/ethnicities other than whites and blacks (e.g., Asians, Hispanics, and Native Americans) were excluded from our analysis. We suggest caution in generalizing our findings to these other races/ethnicities. We do not address whether it is worth estimating T2D risk in older individuals or people with limited life expectancy, although we do include these people in our analysis. We do not specifically evaluate the value of estimating T2D risk in people with low baseline risk, i.e., lean adults aged ,40 years, although such people were also included in our analysis. Our results are not relevant to people with conditions rendering HbA 1c inaccurate (e.g., anemia, renal failure, and some hemoglobinopathies) (51) (52) (53) .
T2D continues to be a major public health problem. Given the evidence for prevention of T2D and its complications through intensive lifestyle intervention or metformin (5, 46) , the importance of identifying high-risk individuals in diverse populations is paramount. Through this investigation, we show evidence supporting the use of HbA 1c for T2D prediction in two major racial groups of the U.S. We evaluated the utility of HbA 1c for identifying high-and low-risk individuals in a variety of common scenarios. HbA 1c is a useful tool for short-term and long-term risk prediction, in itself, and in situations where more clinical information, including fasting measures, is available. This accurate and convenient test has a central place in T2D prevention efforts nationally and worldwide.
